2013 Year-in-Review: Patent Cases at the Federal Circuit

Association for Molecular Pathology v. Myriad Genetics, Inc., 566 U.S. (2012).

Fraser J , Rosen M . Patenting genes in a post-Myriad world. Ind Biotechnol, 2013:9(4):163–164.

Reiter TA , Fasse JP . Isolated, purified, covalent bonds, or magic microscopes? What defines patentable nucleic acid molecules?. Ind Biotechnol, 2011: 7(3):196–199.

Novozymes A/S v. Dupont Nutrition Biosciences APS, 723 F.3d 1336 (Fed. Cir. 2013).

Teva Pharma. USA, Inc. v. Sandoz Inc. 723 F.3d 1363 (Fed. Cir. 2013).

Biosig Instruments Inc. v. Nautilus Inc. 715 F.3d 891 (Fed. Cir. 2013).

Arnon R , Konfino E , Sela M , Teitelbaum D . Copolymer-1 improvements in compositions of copolymers. US Patent No. 5,981,589. 9 November 1999.

Arnon R , Konfino E , Sela M , Teitelbaum D , inventors; Yeda Research and Development Co., assignee. Copolymer-1 improvements in compositions of copolymers. US Patent No. 6,054,430. 25 April 2000.

Teva Pharmaceuticals USA, Inc. v. Sandoz Inc. 876 F.Supp. 2d 295 (S.D.N.Y. 2012)

Id. at 1368.

Id. at 1368.

Id. at 1368.

Id. at 1369.

Id. at 1370.

Id. at 1370.

Id at 1370.

Lekhtman G , inventor; Biosig Instruments, Inc., assignee. Heart rate monitor. US Patent No. 5,337,753. 16 August 1994.

Id. at 897.

Id. at 899.

Id. at 898.

Id. at 898.

Id. at 899.

Id. at 900.

Id. at 902.

Nautilus, Inc. v. Biosig Instruments, Inc. (S. Ct. No. 2013–0369).

Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc. 2013 WL 5202779 (Fed. Cir. Sep. 12, 2013).